BioNTech's Q4 Results Wowed but Were Just the Tip of the Iceberg

It's been a whirlwind for BioNTech (NASDAQ:BNTX) over the last 12 months or so. The German biotech developed what would eventually become the first COVID-19 vaccine to win Emergency Use Authorization (EUA) in the U.S. Its partnership with Pfizer (NYSE:PFE) enabled that vaccine to be produced and distributed in mass quantities.